Clear Search

Showing 34 results for “Systemic Lupus Erythematosus” published 2022.

February 2022

The Interferon Gene Signature as a Clinically Relevant Biomarker in Autoimmune Rheumatic Disease

Lancet Rheumatol 2022;4:e61–72.

The interferon gene signature (IGS) fits into the paradigm of a personalised approach to care in rheumatic diseases, where an individual’s score could inform either prompt diagnosis, early use of certain therapies, or presage specific clinical phenotypes.

more…

Flares after Hydroxychloroquine Reduction or Discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Ann Rheum Dis. 2021:annrheumdis-2021-221295. Epub ahead of print

Evidence suggests that hydroxychloroquine (HCQ) reduction/withdrawal may be safe in some stable patients, but in other settings it may be associated with disease flare. Almeida-Brasil, et al. sought to evaluate SLE flares following HCQ reduction or discontinuation versus HCQ maintenance. Their data suggest that maintaining HCQ was associated with a lower flare risk than reduction or discontinuation, even in patients with low disease activity or remission.

more…

January 2022

2019-EULAR/ACR Classification Criteria Domains at Diagnosis: Predictive Factors of Long-Term Damage In Systemic Lupus Erythematosus

Clin Rheumatol. 2021. Epub ahead of print

Single-centre, retrospective analysis identifying that specific domains in the 2019-EULAR/ACR criteria at diagnosis are associated with long-term organ-specific damage, particularly renal and neuropsychiatric harm.

more…